Novo Nordisk A/S (NVO) AI Stock Analysis

Founded in 1923 and headquartered in Bagsværd, Denmark, Novo Nordisk A/S is a healthcare company focused on pharmaceutical research, development, manufacturing, and marketing. It operates through two primary segments: Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides insulins, GLP-1 analogs, delivery systems, and oral antidiabetic medications, alongside treatments for obesity and chronic diseases. The Biopharm segment provides therapeutic solutions for haemophilia, growth disorders, and hormone replacement therapy. Novo Nordisk also engages in research collaborations with industry partners including Gilead Sciences, Inc. and Lumen Bioscience, Inc.

Between FY2021 and FY2025, Novo Nordisk grew annual revenue from $140.80B to $309.06B, achieving a 5-year revenue CAGR of 19.5% from FY2020 to FY2025. Annual revenue growth slowed from 25.0% in FY2024 to 6.4% in FY2025. Gross margin contracted from 84.7% in FY2024 to 81.0% in FY2025, while operating margin declined from 44.2% to 41.3%. Net income reached $102.43B in FY2025 with diluted EPS of $19.55. For the trailing twelve months ended June 30, 2026, revenue stood at $329.43B with an operating margin of 42.5%. In the latest quarter ended June 30, 2026, quarterly revenue grew 2.1% year-over-year, while quarterly earnings declined 20.6%.

As of June 30, 2026, Novo Nordisk held $44.98B in cash and short-term investments against $140.13B in total debt, resulting in net debt of $95.14B. The current ratio stood at 0.87, and the debt-to-equity ratio was 0.63 against shareholders' equity of $221.28B. In FY2025, operating cash flow reached $119.10B, while capital expenditures totaled $90.11B, resulting in free cash flow of $28.99B. During FY2025, the company allocated $51.76B to dividends paid and $1.39B to share buybacks.

Novo Nordisk closed at $38.83 on October 16, 2026, representing a market cap of $171.36B and an enterprise value of $185.16B. The stock trades at a trailing P/E of 9.1x and a forward P/E of 11.8x, compared to the median of its US-listed Healthcare peers of 24.6x and 17.3x, respectively. Its EV to EBITDA multiple is 8.2x versus 12.0x for the peer median. Over the past year, the stock fell 27.3%, lagging the S&P 500 (SPY) return of 16.8%. Over 5 years, the stock returned -14.9% compared to 83.0% for the S&P 500.

Novo Nordisk pays a semiannual dividend with an annualized forward payout of $1.80 per share, reflecting a dividend yield of 4.63%. The company maintains a payout ratio of 12.7% and has paid dividends for 45 consecutive years. Over the past five years, dividend growth annualized at 20.9%. The most recent ex-dividend date was August 17, 2026.

Wall Street coverage consists of 3 Strong Buy, 10 Hold, and 1 Strong Sell ratings. The mean price target of $45.81 suggests an upside of 18.0% from the last close of $38.83. For the current fiscal year ending December 31, 2026, consensus estimates project EPS of $22.39 and revenue of $301.95B. The company beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 4, 2026.

This page is an AI-written research summary of Novo Nordisk A/S (NVO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NVO income statement, NVO balance sheet, NVO key metrics, NVO analyst forecast, NVO chart. See the NVO stock overview for the latest quote and news.